Dunad Therapeutics Ltd.

→ The top leadership at Lexicon Pharmaceuticals is still undergoing a major makeover as president and COO Jeff Wade heads for the exit on Sept. 30 after 25 years with the Texas-based biotech. Wade won’t be around for the outcome of Lexicon’s latest attempt at an FDA nod in type 1 diabetes for sotagliflozin , which has a Dec. 20 decision date. The drug has already been approved for heart failure and is marketed as Inpefa . Lexicon laid off about 75 people in its sales and commercial teams in August “to right-size our promotional efforts around Inpefa for heart failure and reallocate resources to prepare for our potential launch” in type 1 diabetes and chronic kidney disease, CEO Mike Exton said in a statement. Exton succeeded Lonnel Coats as CEO a month earlier. → Sarepta Therapeutics has appointed Genmab chair Deirdre Connelly to the board of directors. Connelly had a 26-year career with Eli Lilly before pivoting to GSK in 2009 as president, North America pharmaceuticals until her retirement in 2015. She’s also a board member at Macy’s and Lincoln Financial Group . Like Janet Woodcock before him, CBER Director Peter Marks helped Sarepta cross the goal line with a label expansion in June for its Duchenne muscular dystrophy treatment Elevidys — overruling his own staff and befuddling experts. → Mitchell Chan has replaced Vit Vasista as CFO of Regenxbio at a time when the company plans to start a pivotal study for its own Duchenne gene therapy. It’s another big change for Regenxbio after Ken Mills became executive chairman and Curran Simpson succeeded Mills as CEO on July 1. Chan spent a year with Catalio Capital Management as operating partner after he was elevated to the CFO post at Viela Bio. Vasista had been finance chief since 2009 and will be an advisor until Jan. 3. → Here’s a look at some CEO news that we covered earlier this week: Former Kite Pharma commercial chief Warner Biddle has succeeded Peter Maag as CEO of Kyverna Therapeutics , which also added ex-Kite CEO Christi Shaw to the board. Shares $KYTX of Kyverna have taken a precipitous fall since its $319 million IPO in February. Ochre Bio co-founder Jack O’Meara is calling it quits after five years as CEO, but he tells Lei Lei Wu that he has an Alzheimer’s startup in the works. In a LinkedIn post announcing his departure, O’Meara also said that former F-star CEO and current Levicept chief Eliot Forster will be interim executive chair. And Shilpa Sambashivan has been promoted to CEO of Nura Bio , which stapled an additional $68 million to its Series A — bringing its total to $141 million. Sambashivan was a project team lead at Amgen before becoming a founding member at Nura Bio. → Matt Kane is taking the top spot at Celyad Oncology , a Belgian biotech that has seen considerable turnover at the top. Celyad co-founder Michel Lussier filled in as interim CEO for a second time after Georges Rawadi ’s sudden exit last December; he also took over when Filippo Petti stepped down in 2022. Kane co-founded Precision BioSciences with Derek Jantz and Jeff Smith , leading the company until he joined epigenome editing startup Tune Therapeutics as CEO in 2021. Kane’s LinkedIn page indicates that he left Tune in April, a year after he hired Jantz as CSO. → Ex- Prometheus Biosciences chief Mark McKenna has found a CFO at his new I&I bet, Mirador Therapeutics . Gregg Gilbert had been a managing director in the healthcare investment banking group for Bank of America Securities since 2021 and worked at Bank of America Merrill Lynch for 15 years. After selling Prometheus and its inflammatory bowel disease drug to Merck for $10.8 billion , McKenna wasted little time getting Mirador off the ground with a $400 million Series A in March, one of the largest private financing rounds of 2024. → GLP-1 competitor Structure Therapeutics has promoted Blai Coll to CMO and welcomed Ashley Hall as chief development officer. Coll, who replaces Mark Boch , had led clinical development for Raymond Stevens ’ crew since May 2022 and was cardiovascular and metabolic platform lead, medical affairs at the end of a six-year stint with Amgen. Hall is an Amgen vet in her own right who held the role of development chief at Reneo Pharmaceuticals . Structure’s stock price soared in June $GPCR when it produced efficacy data with its oral GLP-1 GSBR-1290 that was on par with Eli Lilly’s obesity drug orforglipron . → Novartis and Gilead veteran Matthias Will has succeeded Edgar Braendle as chief development officer at Autolus Therapeutics . Will had led clinical development at CRISPR Therapeutics and CytomX before his most recent gig as CMO of Dren Bio . The FDA is expected to make a decision by Nov. 16 on Autolus’ CD19-directed CAR-T obecabtagene autoleucel , or obe-cel . → According to an SEC filing , Crinetics chief commercial officer Jim Hassard will pack his bags on Oct. 14 in what’s described as a “termination without cause.” The 17-year Amgen vet came to Crinetics from Arrowhead Pharmaceuticals in March 2022. Phase 3 successes with its acromegaly drug paltusotine have propelled Crinetics to an NDA filing “later this year” and “an expected market launch in 2025,” CEO Scott Struthers said in the San Diego biotech’s second-quarter report. CFO Mark Wilson cited personal reasons for his own upcoming departure, which was also included in Crinetics’ Q2 update. → Allosteric drug discovery shop HotSpot Therapeutics has introduced Alison O’Neill as CMO. O’Neill is the former medical chief at Surface Oncology , which was acquired by Coherus BioSciences last year for $65 million. She had a senior leadership role in the global oncology division at Sanofi and was VP of clinical development for Radius Health . → Ex- Icosavax CEO Adam Simpson has landed at Frazier Life Sciences as a venture partner on its company creation team and will work out of Frazier’s office in San Diego. Simpson sold the vaccine developer to AstraZeneca last December, and his previous company — celiac disease specialist PvP Biologics — was purchased by Takeda in 2020. → Ruben Tommasi has been named CSO of Entact Bio , a Watertown, MA-based biotech led by ex- Ribon Therapeutics CEO Victoria Richon that is developing enhancement-targeting chimeric molecules, or ENTACs. Tommasi has also held this role at Dunad Therapeutics and AstraZeneca spinout Entasis Therapeutics . Entact Bio has kept a relatively low profile since its $81 million Series A in 2022, but it did show up in Peer Review this spring when it recruited fellow Entasis vet Michael Gutch as COO. → Third Rock ’s Treg developer Abata Therapeutics has resurfaced in Peer Review for the first time in more than a year, naming Joanne Beck as chief technical officer. The Shire and Celgene alum is the ex-technical chief at Aerium Therapeutics , the Covid biotech led by Rajeev Venkayya that recently shut down because of a surge in new variants. In April 2023, Abata poached Sonoma Biotherapeutics CMO Leonard Dragone for the same role . → Led by ex- Teva R&D chief Michael Hayden , neuro biotech Prilenia has tapped Rob Lauzen as CFO and Jason Marks as chief legal officer. Lauzen was VP, investor relations and head of financial planning & analysis at Dyne Therapeutics , which made a CMO change and lost its COO and CBO earlier this month. Marks just had a short stint with Teva as a senior legal advisor to global transactions and global finance. The Bausch Health alum has also been chief legal and compliance officer at Amarin . → San Francisco eye disease biotech Ray Therapeutics has selected Christopher Whitmore as CFO. Whitmore had held the same position with Immune-Onc Therapeutics since July 2022, and he was VP, finance & administration for Harpoon Therapeutics from 2018-21. Ray Therapeutics, which hauled in a $100 million Series A last year, will test its gene therapy RTx-015 in patients with retinitis pigmentosa. → Tris Pharma has promoted VP of marketing Manesh Naidu to the role of chief commercial officer. Naidu joined the New Jersey-based company in 2023 after a stint as chief marketing officer of Althera Pharmaceutical . Naidu’s résumé also includes stints at McKinsey , Mallinckrodt , Novartis, Pfizer and Bellerophon Therapeutics . In May, Tris snagged the first liquid non-stimulant ADHD drug approval in the US. Onyda XR will be used to treat ADHD in children at least 6 years of age. → Backed by Jeff Bezos , Seattle-based Nautilus Biotechnology has named Kentaro Suzuki as chief marketing officer. Suzuki most recently served as VP and general manager of Agilent Technologies’ mass spectrometry division. Before that, he was with Takeda and Hewlett-Packard . → San Francisco-based 89bio has appointed Teresa Perney as chief regulatory and quality officer. Perney held this title at EQRx after five years with Myovant Sciences as SVP of regulatory and quality. Madrigal Pharmaceuticals finally broke through with an FDA approval for metabolic dysfunction-associated steatohepatitis (also referred to as NASH), and 89bio is enrolling patients for late-stage studies of pegozafermin — one for non-cirrhotic MASH and another for MASH with compensated cirrhosis. “I’m eager to leverage my experience to navigate the regulatory landscape and help bring this innovative therapy to patients worldwide,” Perney said in a statement . → There’s also a new regulatory chief at Disc Medicine : Steve Caffé spent five years with CRISPR Therapeutics as head of regulatory affairs until his departure last December. Earlier, he had numerous stops as a regulatory exec with such companies as Ra Pharmaceuticals , Sucampo Pharmaceuticals , AMAG Pharmaceuticals and MedImmune . Shares of Disc $IRON fell sharply in early April after mixed data with its drug for a rare blood disorder called erythropoietic protoporphyria, but have rebounded since. → Although AI-designed drugs haven’t exactly lived up to the hype, companies like BPGbio are trying to flip the narrative. This week, GSK alum John Beeler has joined the team as SVP of business development. Beeler comes to BPGbio from Bristol Myers Squibb , where he took on the role of business development search & evaluation lead. → Macrocycle startup Circle Pharma has brought in Marie Evangelista as SVP and head of cancer biology, and promoted Constantine Kreatsoulas to SVP and head of discovery technology sciences. Evangelista spent the last two years as VP of oncology at one of the most ambitious AI drug developers , Recursion . The longtime Genentech vet also had a brief tenure with Frontier Medicines as senior director of translation medicine. Kreatsoulas had a nine-year run at GSK and was the pharma giant’s interim head, computational toxicology before coming to Circle in 2021 as head of research and VP, research informatics and computational chemistry. Circle disclosed its $54 million Series D in an SEC filing this summer. → South San Francisco-based Ideaya Biosciences has recruited Douglas Snyder as general counsel. Snyder most recently served as chief legal officer and secretary of GW Pharmaceuticals . Earlier in his career, Snyder was general counsel and secretary at Actelion and Eisai . Back in July, Ideaya inked a $406.5 million deal with Biocytogen . → Deerfield Group has rolled out the welcome mat for two new execs: Guy Varady as EVP, integrated marketing and Bob Josefsberg as EVP, communications. Before this, Varady was SVP, management supervisor for DDB Health and held a number of roles at IPG Health and Omnicom Health Group . Meanwhile, Josefsberg was VP, corporate communications at Karuna Therapeutics and managing director at Chamberlain Healthcare Public Relations . → Tempest Therapeutics , which revealed early PFS and OS data for its liver cancer combo last October, has brought on Sheldon Mullins as VP, regulatory affairs. Mullins joins the team after gigs at Arrowhead Pharmaceuticals and Ardelyx . Earlier in his career, Mullins was with Anacor Pharmaceuticals , Onyx Pharmaceuticals and Genentech. In addition to Mullins’ appointment, Darrin Bomba and Henry Johnson have been promoted to the titles of VP, development operations and VP, CMC & medicinal chemistry, respectively. → Entrada Therapeutics CEO Dipal Doshi has picked up a seat on the board of directors at āshibio , a California biotech that will push its ex-Gilead drug andecaliximab into a Phase 2/3 study for patients with an ultra-rare bone disorder called fibrodysplasia ossificans progressiva (FOP). Āshibio came out of stealth mode this summer with a $40 million raise . → Akari Therapeutics , which is developing PAS-nomacopan for geographic atrophy, has elected former Epizyme CEO Rob Bazemore to the board of directors. Bazemore is also a board member at Ardelyx and Nuvation Bio .

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 AUROBAC THERAPEUTICS, a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, today announced the creation of its Scientific Advisory Board (SAB) and the appointment of its members. Comprised of distinguished experts in preclinical and clinical drug development, diagnostics, and infectious diseases, the SAB will provide scientific and medical expertise as well as strategic guidance to support AUROBAC’s R&D strategy and to help advance its first products to clinical trials. The SAB duties will also include program execution considerations in the framework of innovation, clinical and market dynamics. “We are thrilled to welcome such a qualified and experienced group of experts to our Scientific Advisory Board”, said Florence Séjourné, CEO of AUROBAC THERAPEUTICS. “Their collective expertise and insights will be invaluable as we navigate the complexities of developing innovative products targeting bacterial infections, antimicrobial resistance and their consequences in acute hospital settings. The creation of the SAB is a significant milestone for AUROBAC, underscoring our commitment to scientific excellence and innovation.” The newly formed SAB will be chaired by Dr. Marco Taglietti, who is also an Independent Member of AUROBAC’s Board, and consists of: Sujata M. Bhavnani, PharmD, M.S., is a distinguished pharmacokinetics-pharmacodynamics expert for antimicrobial agents. Her work has supported decisions for dose selection and interpretive criteria for the in vitro susceptibility testing for numerous new drug applications. She is the Executive Vice-President of Translational Medicine for ICPD (Institute for Clinical Pharmacodynamics). She received her Pharm.D. from the Albany College of Pharmacy, completed a two-year post doctorial fellowship in infectious diseases and pharmacokinetics at Millard Fillmore Hospital, and her M.S. in biometry from the University at Buffalo.Mark Miller, MD, is a renowned medical clinician, microbiologist and clinical researcher with expertise in infectious disease and epidemiology. Until recently, he was Chief Medical Officer, Executive Vice-President and was on the Executive Management Committee at bioMérieux for 11 years (2012 – 2024). Prior to bioMérieux, he was Head of Infectious Diseases, Chief of Clinical Microbiology, and Chair of Infection Prevention and Control at the Jewish General Hospital (Montreal, Canada) for over 25 years, until 2012. He received his MD with further specialization in Internal Medicine, Infectious Diseases and Medical Microbiology and his M.Sc. in Epidemiology and Biostatistics from McGill University (Montreal, Canada) where he was appointed a Full Professor of Medicine in 2012.Manu Shankar-Hari, MD, Ph.D., M.Sc., is a clinician scientist with an outstanding expertise in translational research and immunology of sepsis. Currently, he holds the Personal Chair of Translational Critical Care Medicine at the Institute for Regeneration and Repair (University of Edinburgh). He leads a globally unique precision medicine program for critically ill adults to enable targeted immunomodulation (The TRAITS programme). For additional details of Prof Shankar-Hari’s research, please see academic webpage.Ruben Tommasi, Ph.D., has extensive expertise in preclinical development with almost 30 years’ of industry and biotech experience. He is currently Chief Scientific Officer of Dunad Therapeutics since 2022. Prior to Dunad, he was a founding leader and Chief Scientific Officer at Entasis Therapeutics (2015 – 2022). He also spent 4 years at AstraZeneca as Executive Director, Chemistry, of the Infection Innovative Medicines unit, after having been at Novartis for 17 years where he led several medicinal chemistry efforts, most recently the Infectious Disease Therapy unit. He received a Ph.D. in organic chemistry from the State University of New York at Albany.Richard G. Wunderink, MD, is a highly-experienced clinician scientist, active in pulmonary infections and sepsis. He is a professor of medicine in the Pulmonary and Critical Care Division of Northwestern University’s Feinberg School of Medicine and formerly medical director of the MICU, Northwestern Memorial Hospital. He co-chaired the 2007 IDSA (Infectious Diseases Society of America) / ATS (American Thoracic Society) Consensus Guidelines Committee on the management of community-acquired pneumonia. He was a member of previous ATS/IDSA guidelines committee on HAP/VAP and the ERS/ESCIM/ESCMID/ALAT International Guidelines for the Management of HAP/VAP and the recently published ERS/ESCIM/ESCMID/ALAT guidelines for management of Severe CAP. He received his MD from the Indiana University School of Medicine. “I am honoured to take on the role of Chairman of AUROBAC's SAB and look forward to working together with these esteemed scientists to support the development of products addressing antimicrobial resistance, one of the biggest public health threats of our time”, said Dr. Marco Taglietti, Chairman of the SAB. Leveraging the invaluable expertise of the SAB, the AUROBAC team is well prepared to advance its product pipeline and provide effective treatments for patients with severe bacterial infections. About AUROBAC THERAPEUTICS: AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux. Dedicated to addressing high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial resistance (AMR) epidemic, AUROBAC is advancing a robust pipeline. This includes ATX101, a potential first-in-class therapeutic targeting the loss of vascular integrity in septic shock, developed in collaboration with Boehringer Ingelheim, and ATX401, an engineered lysin with potent activity against multiple clinically relevant Gram-negative bacteria. Additionally, the company’s unique drug discovery engine aims to identify new precision antimicrobials, as showcased through a collaboration with GENERARE Bioscience. Contact: Julie Cervesi, Head of Business Development - Mail: contact@aurobac-tx.comWebsite: aurobac-tx.comLinkedin: https://linkedin.com/company/aurobac-tx/X: https://x.com/AurobacTX

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Mirati CEO Meek steps down after Krazati’s hot and cold spell Mirati Therapeutics A topsy-turvy year for Mirati Therapeutics has taken its latest turn, with CEO David Meek stepping down this week effective immediately. The move has forced outgoing president Charles Baum, M.D., Ph.D., to place his own departure plans on hold, taking the CEO reins on an interim basis. Meek will stay on as a consultant for the next two months. No explanation was provided for Meek's departure, though fellow colleagues lauded him in a press release. Mirati Chairman Faheem Hasnain thanked Meek for his “significant impact” to growing the business and overseeing the development and FDA approval of Krazati and Baum said peers “extend our sincere gratitude to David.”  Mirati was the talk of the town earlier this year, fresh off accelerated approval of KRAS-targeting Krazati in December, setting up a showdown with Amgen’s Lumakras. The approval potential had spurred potential takeover interest at the tail end of the year. The company reported that the med raked in $13.4 million in revenue in the second quarter, above investor expectations.  But European regulators set the company back last month when they declined to greenlight the treatment, also known as adagrasib. The company has since said that they plan to formally ask the European Medicines Agency to reconsider. A little more than two weeks later, Meek's resignation was announced. Fierce Pharma  2 more Illumina execs depart amid sinking projections, SEC investigation Illumina Illumina announced during its latest earnings presentation that two more execs are set to leave the company while simultaneously cutting the earnings forecast for this year. The testing giant now expects earnings from its business to roughly stay the same compared to 2022, growing about 1%. The company previously projected growth of 7% to 10%. A subsequent regulatory filing included a potentially even larger concern—Illumina says the US Security and Exchanges Commission reached out in July to let them know they were under investigation and that officials requested documents and communications related to the acquisition of GRAIL. Gulp!  Illumina will navigate these treacherous waters without Chief Medical Officer Phil Febbo, M.D., and Chief Technology Officer Alex Aravanis, M.D., Ph.D., who are both leaving the company.  Illumina made no mention of who will replace Febbo but announced Steven Barnard, Ph.D., will replace Aravanis. Barnard was previously VP and head of global advanced science and he’s been a fixture at the company since joining in 1998, notably the fourth employee and first scientist hired. While leading the global advanced science team, Barnard helped launch the NovaSeq X, a state-of-the-art unit that can perform whole genome sequencing, whole exome sequencing and whole transcriptome sequencing. Earnings presentation  Foghorn to switch up CMO in September after clinical holds stymie progress Foghorn Therapeutics Foghorn is making a switch at chief medical officer, with existing exec Sam Agresta, M.D., set to be replaced by Alfonso Quintás-Cardama, M.D., in September. Agresta will provide consulting services through the remainder of the year.  CEO Adrian Gottschalk thanked Agresta in a release for his contributions over his four-year tenure, during which the company launched its first clinical assets. Foghorn’s lead asset, FHD-286, is in a phase 1 trial though it dealt with a significant clinical hold that last 10 months. The company announced in June that it’d no longer advance the asset as a treatment for uveal melanoma and instead focus on launching a phase 1 combination study in patients with relapsed or refractory acute myeloid leukemia. Getting that trial off the ground will likely be one of the top priorities for Quintás-Cardama when he takes over. But he’ll also have to work with the FDA to lift a second clinical hold on cancer med FHD-609, which had the clamps placed down in April. The company made no mention of the asset in its second-quarter earnings report earlier this month. Release > Voyager Therapeutics is welcoming aboard Beth Shafer, Ph.D., to serve as chief business officer. Shafer joins the gene therapy biotech from Takeda, where she most recently held the role of VP and head of R&D business development, gastrointestinal and inflammation, neuroscience, drug discovery sciences, externalizations. Release > Vivoryon Therapeutics Chief Medical Officer Frank Weber, M.D., is set to take the reins from CEO Ulrich Dauer, Ph.D., on Aug. 14. Weber joined Vivoryon in 2010 and will be supported by the company’s current head of investor relations, Anne Doering, who will step into the newly created position of chief strategy and investor relations officer. Release > Viracta Therapeutics has tapped Darrel Cohen, M.D., Ph.D., to take on the role of chief medical officer. Before joining the oncology company, Cohen most recently served as CMO of cell therapy at Athenex and has past experience at Biosight Pharmaceuticals, EUSA Pharma, Pharmacia, Sanofi-Aventis and Pfizer. Release > It’s the week of executive moves for biotechs that start with the letter “V,” and Vigil Neuroscience is no exception. The neurodegenerative-disease-focused company is welcoming Christopher Silber, M.D., on as chief medical officer. The leader joins from Nocion Therapeutics, where he also served as CMO, and before that served as Sage Therapeutics’ SVP of clinical development. Release > Tango Therapeutics Chief Scientific Officer Alan Huang, Ph.D., is ending his dance with the cancer company in October. In his place steps Jannik Andersen, Ph.D., Tango’s current head of biology. Release > Avalyn Pharma has appointed Howard Lazarus, M.D., to breathe life into its team in the newly formed role of chief medical officer. Lazarus most recently served as CMO for Altavant Sciences (acquired by Enzyvant), and earlier worked at Boehringer Ingelheim and Gilead Sciences. Release > As Ankyra Therapeutics prepares to bring its first asset to the clinic, the cancer company is welcoming Robert Tighe on as chief scientific officer. He started off his career as a research assistant in the lab of Robert Weinberg, Ph.D., at the Massachusetts Institute of Technology, and has worked at EMD Serono, Compass Therapeutics and TCR2 Therapeutics since. Release > Indaptus Therapeutics has tapped Roger Waltzman, M.D., to be the biotech’s chief medical officer. Waltzman joins from Molecular Templates, and has previously held leadership roles at Rgenix (now Inspirna), Jaguar Health and Novartis. Release > Kytopen has signed on Michael Chiu, Ph.D., to succeed company co-founder Paulo Garcia, Ph.D., as the biotech’s CEO. Prior to Kytopen, Chiu was CEO of Erbi Biosystems, which was acquired by Merck KGaA last year. Release > Processa Pharmaceuticals has picked George Ng to lead the company as CEO and director of the board. Ng is currently a partner at PENG Life Science Ventures joins Processa from Calidi Biotherapeutics, where he served as president and chief operating officer. Release > England-based Dunad Therapeutics has selected Jonathan Garen to serve as chief business officer. Before Dunad, Garen was CBO for Nocion Therapeutics and uniQure. Release > Platform company Auron Therapeutics has hired Christopher Guiffre to serve as president and chief operating officer. Guiffre joins from Pear Therapeutics, where he was chief financial officer and chief operating officer since 2017. Release > Christophe Arbet-Engels, M.D., Ph.D., is set to join X4 Pharmaceuticals as chief medical officer. He previously held the CMO spot at several other biopharmas and also held a range of senior positions at Biogen, Boehringer Ingelheim Pharmaceuticals, Hoffmann-La Roche, Merck Research Laboratories, Aventis Pharmaceuticals and Ligand Pharmaceuticals. Release > AI Proteins Chief Operating Officer Noah Beerman is taking the lead as CEO of the biotech. Former CEO Drew Dennison has stepped down but will continue to chair the nominating and governance committee and serve as a board director. Release > Deciphera Pharmaceuticals founder, EVP and Chief Scientific Officer Daniel Flynn, Ph.D., is set to retire Sept. 5. Dashyant Dhanak, Ph.D., Incyte’s EVP and CSO, will take Flynn’s place. Release